Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of December 2022).
In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.
Program (Target) | Potential Indication(s) | First-in-Human (Phase 1) | Proof-of-Concept (Phase 2) |
Pivotal (Phase 3) |
Major Market Rights | ||
---|---|---|---|---|---|---|---|
Vobramitamab Duocarmazine (MGC018) (B7-H3) |
mCRPC (TAMARACK study) |
placeholder
|
![]() |
||||
Multiple Solid Tumors (+lorigerlimab) |
placeholder
|
||||||
Lorigerlimab (PD-1 × CTLA-4) |
mCRPC, Melanoma, MSS CRC, NSCLC |
placeholder
|
![]() |
||||
Tebotelimab (PD-1 × LAG-3) |
Solid Tumors & Heme Malignancies |
placeholder
|
![]() |
Greater China![]() |
|||
MGD024 (CD123 × CD3) |
CD123+ Heme Malignancies |
placeholder
|
![]() |
Option Agreement![]() |
|||
IMGC936 (ADAM9) |
Multiple Solid Tumors |
placeholder
|
50/50 ![]() ![]() |
||||
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights: